Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Darolutamide + VIR-5500 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Darolutamide | Nubeqa | BAY1841788|ODM-201 | Hormone - Anti-androgens 59 | Nubeqa (darolutamide) is an androgen receptor antagonist that binds to and prevents nuclear translocation of the androgen receptor, thereby inhibiting expression of genes downstream of androgen receptor signaling that regulate proliferation of prostate cancer cells (PMID: 28490267). Nubeqa (darolutamide) is FDA approved for use in patients with non-metastatic castration-resistant prostate cancer, and as monotherapy or in combination with docetaxel in patients with metastatic hormone-sensitive prostate cancer (FDA.gov). |
| VIR-5500 | AMX-500|AMX500|AMX 500|SAR446329|SAR-446329|SAR 446329|VIR5500|VIR 5500 | VIR-5500 (AMX-500) is a dual-masked bispecific T-cell engager that targets FOLH1 (PSMA), which is activated in the tumor microenvironment and potentially induces antitumor activity (J Clin Oncol 44: 16_Suppl, 17). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|